Novel furan chalcone modulates PHD-2 induction to impart antineoplastic effect in mammary gland carcinoma

Shubham Rastogi1, Mohd Nazam Ansari2, Abdulaziz S Saeedan2

  • 1Department of Pharmaceutical Sciences, School of Biomedical and Pharmaceutical Sciences, Babasaheb Bhimrao Ambedkar University (A Central University), Lucknow, Uttar Pradesh, India.

Insights

This study identified BBAP-7 as a novel prolyl hydroxylase-2 (PHD-2) activator. BBAP-7 demonstrates anticancer properties by inducing apoptosis and restoring mammary gland structure, offering a promising new cancer therapy.

Area of Science:

  • Oncology
  • Molecular Biology
  • Drug Discovery

Background:

  • Normoxic inactivation of prolyl hydroxylase-2 (PHD-2) promotes tumor growth via HIF-1α and NF-κB.
  • Targeting PHD-2 is a potential strategy for cancer therapy.

Purpose of the Study:

  • To identify small molecule activators of PHD-2.
  • To evaluate the anticancer efficacy of identified PHD-2 activators.

Main Methods:

  • Virtual screening of 265,242 compounds for furan chalcone scaffold similarity.
  • In vitro PHD-2 activation assay (2-oxoglutarate assay).
  • Cytotoxicity and apoptosis assays (MTT, DAPI, JC-1, AO/EB) on MCF-7 cells.
  • In vivo antineoplastic efficacy study using a DMBA-induced mammary gland cancer model.

Main Results:

  • BBAP-7 identified as a potent PHD-2 activator.
  • BBAP-7 exhibits significant cytotoxicity against MCF-7 cells (IC50 = 18.84 µM) and induces apoptosis.
  • In vivo studies show BBAP-7 restores mammary gland morphology, reduces oxidative stress, and glycolysis.

Conclusions:

  • BBAP-7 is a validated PHD-2 activator with promising anticancer properties.
  • BBAP-7 demonstrates therapeutic potential for mammary gland cancer by targeting key oncogenic pathways.